Buscar
Immunome Inc
IMNMAñadir a la lista de seguimiento
24.240USD
-1.510-5.86%
Cierre 09-23 16:00（ET）
2.75BCap. mercado
PérdidaP/E TTM
Acerca de Immunome Inc Compañía
Immunome, Inc. is a clinical-stage targeted oncology company, which is focused on developing first-in-class and targeted therapies designed to improve outcomes for cancer patients. The Company is engaged in advancing an innovative portfolio of therapeutics in the design, development, and commercialization of targeted cancer therapies, including antibody-drug conjugate therapies (ADCs). Its advanced pipeline programs are varegacestat, a gamma secretase inhibitor which is in a Phase III trial for the treatment of desmoid tumors; IM-1021, an ROR1-targeted ADC which is in a Phase I trial, and IM-3050, a FAP-targeted radioligand. The Company's pipeline also includes IM-1617, IM-1335, and IM-1340, all of which are preclinical ADCs pursuing undisclosed targets with expression in multiple solid tumors. IM-1617 is a potential first-in-class ADC that targets an undisclosed receptor that is expressed in a range of solid tumors, including colorectal cancer and ovarian cancers.
Perfil de Immunome Inc
Símbolo de cotizaciónIMNM
Nombre de la empresaImmunome Inc
Fecha de salida a bolsaOct 02, 2020
Director ejecutivoSiegall (Clay B)
Número de empleados118
Tipo de seguridadOrdinary Share
Fin del año fiscalOct 02
Dirección18702 N. Creek Parkway
CiudadBOTHELL
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal98011
Teléfono16103213700
Sitio Webhttps://immunome.com/
Símbolo de cotizaciónIMNM
Fecha de salida a bolsaOct 02, 2020
Director ejecutivoSiegall (Clay B)
Ejecutivos de Immunome Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Clay B. Siegall, Ph.D.
Dr. Clay B. Siegall, Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
870.70K
+20.67%
Dr. Clay B. Siegall, Ph.D.
Dr. Clay B. Siegall, Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
870.70K
+20.67%
Dr. Clay B. Siegall, Ph.D.
Dr. Clay B. Siegall, Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
870.70K
+20.67%
Mr. Philip R. Wagenheim
Mr. Philip R. Wagenheim
Director
Director
341.15K
-19.05%
Mr. Philip R. Wagenheim
Mr. Philip R. Wagenheim
Director
Director
341.15K
-19.05%
Mr. Philip R. Wagenheim
Mr. Philip R. Wagenheim
Director
Director
341.15K
-19.05%
Mr. Kinney Horn
Mr. Kinney Horn
Chief Business Officer
Chief Business Officer
238.96K
--
Mr. Kinney Horn
Mr. Kinney Horn
Chief Business Officer
Chief Business Officer
238.96K
--
Mr. Kinney Horn
Mr. Kinney Horn
Chief Business Officer
Chief Business Officer
238.96K
--
Mr. Max Rosett
Mr. Max Rosett
Chief Financial Officer
Chief Financial Officer
101.29K
+46.65%
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Clay B. Siegall, Ph.D.
Dr. Clay B. Siegall, Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
870.70K
+20.67%
Dr. Clay B. Siegall, Ph.D.
Dr. Clay B. Siegall, Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
870.70K
+20.67%
Dr. Clay B. Siegall, Ph.D.
Dr. Clay B. Siegall, Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
870.70K
+20.67%
Mr. Philip R. Wagenheim
Mr. Philip R. Wagenheim
Director
Director
341.15K
-19.05%
Mr. Philip R. Wagenheim
Mr. Philip R. Wagenheim
Director
Director
341.15K
-19.05%
Mr. Philip R. Wagenheim
Mr. Philip R. Wagenheim
Director
Director
341.15K
-19.05%
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Immunome Inc?
Los cinco principales accionistas de Immunome Inc son: Dr. Clay B. Siegall, Ph.D.
¿Cuántas instituciones poseen acciones de Immunome Inc (IMNM)?
A fecha de 2026Q1, 380 instituciones poseen acciones de Immunome Inc, con un valor de mercado combinado de aproximadamente 116.25M, lo que representa el 102.66% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en 15805031.00.